Oxford Biodynamics PLC
LSE:OBD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (0), the stock would be worth GBX-0 (102% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.3 | GBX0.24 |
0%
|
| Industry Average | 0 | GBX-0 |
-102%
|
| Country Average | 0 | GBX-0 |
-101%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Oxford Biodynamics PLC
LSE:OBD
|
10.8m GBP | -1.3 | -0.9 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 1 225.9 | 4 278.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
197.4B USD | 20 | 28.9 | |
| US |
|
Danaher Corp
NYSE:DHR
|
137.5B USD | 18.5 | 36.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 30.1 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
35.1B CHF | 16.9 | -124.9 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
294B CNY | 16 | 15.4 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.5B USD | 19.5 | 26.5 | |
| US |
|
Waters Corp
NYSE:WAT
|
32.9B USD | 32.8 | 50.8 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.8B USD | 12.1 | 22 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27B USD | 22.8 | 30.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 743.2 |
Other Multiples
Oxford Biodynamics PLC
Glance View
Oxford BioDynamics Plc is a biotechnology company, which engages in the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The firm is engaged in advancing personalized healthcare by developing and commercializing medicine tests for life-changing diseases. The company has developed a three dimensional (3D) genomic biomarker platform, EpiSwitch, which builds molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a range of indications. The platform discovers, evaluates, validates and monitors of biomarkers known as chromosome conformation signatures (CCSs). CCSs provides a compelling, stable framework from which changes in the regulation of a genome can be analyzed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities. EpiSwitch supports precision medicine initiatives, including prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring.
